ARTICLE | Financial News
Puma soars on neratinib news
July 24, 2014 12:58 AM UTC
Puma Biotechnology Inc. (NYSE:PBYI) jumped $174.40 (295%) to $233.43 on Wednesday after the company reported top-line data for oral neratinib (PB272) as adjuvant treatment of HER2-positive breast canc...